Detection of acute myeloid leukaemia (AML) leukaemic stem cells (LSC)
View Patent ↗The present invention relates to diagnostic screens, gene expression profiles, methods and kits for detection of acute myeloid leukaemia leukaemic stem cells. Diagnostic and prognostic methods based on said diagnostic screens and/or gene expression profiles also form part of the invention.
1. A method for detecting acute myeloid leukaemia (AML) leukaemic stem cells (LSCs) comprising:
i. contacting an isolated sample containing a blood cell population with:
a first antibody that specifically binds to CD34;
a second antibody that specifically binds to CD48;
a third antibody that specifically binds to CD117;
a fourth antibody that specifically binds to CD150; and
a fifth antibody that specifically binds to CD244; and
ii. detecting:
the absence of binding between the first, second, and fourth antibodies and a blood cell comprised in said isolated sample, and the presence of binding between the third and fifth antibodies and said blood cell; or
the absence of binding between the first, second, fourth, and fifth antibodies and said blood cell, and the presence of binding between the third antibody and said blood cell;
thereby confirming that said blood cell is an AML LSC; or
iii. not detecting:
the absence of binding between the first, second, and fourth antibodies and a blood cell comprised in said isolated sample, and the presence of binding between the third and fifth antibodies and said blood cell; or
the absence of binding between the first, second, fourth, and fifth antibodies and said blood cell, and the presence of binding between the third antibody and said blood cell;
thereby confirming that said blood cell is not an AML LSC.
2. The method according to claim 1 further comprising contacting the isolated sample with one or more selected from the group consisting of:
an antibody that specifically binds to CD2;
an antibody that specifically binds to CD3;
an antibody that specifically binds to CD4;
an antibody that specifically binds to CD8a;
an antibody that specifically binds to CD10;
an antibody that specifically binds to CD19;
an antibody that specifically binds to CD20; and
an antibody that specifically binds to CD235a.
3. A method for determining the prognosis and treatment of acute myeloid leukaemia and/or a symptom thereof, comprising:
i. contacting an isolated sample obtained from a patient containing a blood cell population with:
a first antibody that specifically binds to CD34;
a second antibody that specifically binds to CD48;
a third antibody that specifically binds to CD117,
a fourth antibody that specifically binds to CD150; and
a fifth antibody that specifically binds to CD244;
ii. detecting:
the absence of binding between the first, second, and fourth antibodies and a blood cell comprised in said isolated sample, and the presence of binding between the third and fifth antibodies and said blood cell; or
the absence of binding between the first, second, fourth, and fifth antibodies and said blood cell, and the presence of binding between the third antibody and said blood cell; and
iii. administering to said patient a therapy for acute myeloid leukaemia and/or a symptom thereof.
4. The method according to claim 3 further comprising contacting the isolated sample with one or more selected from the group consisting of:
an antibody that specifically binds to CD2;
an antibody that specifically binds to CD3;
an antibody that specifically binds to CD4;
an antibody that specifically binds to CD8a;
an antibody that specifically binds to CD10;
an antibody that specifically binds to CD19;
an antibody that specifically binds to CD20; and
an antibody that specifically binds to CD235a.
5. A method of treating acute myeloid leukaemia in a patient comprising:
i. requesting performance of the method of claim 1 and/or obtaining the results of the method of claim 1 ; and
ii. administering to said patient a therapy for acute myeloid leukaemia (AML) if the presence of acute myeloid leukaemia (AML) leukaemic stem cells (LSC) is confirmed.